US stock · Healthcare sector · Drug Manufacturers—General
Company Logo

Gilead Sciences, Inc.

GILDNASDAQ

86.36

USD
+1.86
(+2.20%)
After Hours Market
32.01P/E
12Forward P/E
1.45P/E to S&P500
107.691BMarket CAP
3.46%Div Yield
Upcoming Earnings
26 Apr-1 May
Shares Short
1/13/23
14.93M
Short % of Float
1.19%
Short % of Shares Outs.
1.19%
% Held by Insiders
0.08%
% Held by Institutions
84.57%
Beta
0.43
PEG Ratio
4.92
52w. high/low
89.74/57.17
Avg. Daily Volume
7.39M
Return %
Stock
S&P 500
1 year
30.52
(7.99)
3 years
24.30
23.80
5 years
7.29
56.27
Scale: |
High
Low
28.82
17.80
26.64
20.31
24.75
15.86
21.75
17.23
38.56
20.67
76.11
36.94
116.83
63.50
123.37
86.00
103.10
70.83
86.27
63.76
89.54
60.32
70.50
60.89
85.97
56.56
74.12
57.93
89.74
57.17
88.29
80.48
Currency: USD
2007
2008
2009
2010
2011
2012
2013
2014
2015
2016
2017
2018
2019
2020
2021
2022
Revenue per share
2.28
2.90
3.88
4.64
5.41
6.41
7.33
16.35
22.29
22.70
19.97
17.05
17.68
19.64
21.74
21.74
Earnings per share
0.87
1.09
1.46
1.69
1.81
1.71
2.01
7.95
12.37
10.08
3.54
4.20
4.24
0.10
4.96
3.66
FCF per share
0.91
1.13
1.58
1.62
2.26
1.85
1.91
8.06
13.38
11.89
8.65
5.76
6.55
5.98
8.60
7.23
Dividends per share
- -
- -
- -
- -
- -
- -
- -
- -
1.28
1.83
2.09
2.29
2.54
2.74
2.87
- -
CAPEX per share
0.04
0.06
0.13
0.04
0.09
0.26
0.12
0.37
0.51
0.56
0.45
0.71
0.65
0.52
0.46
- -
Book Value per sh.
1.86
2.26
3.52
3.42
4.35
6.15
7.44
10.14
12.66
14.11
15.64
16.48
17.74
14.48
16.77
- -
Comm.Shares outs.
1,858
1,841
1,809
1,712
1,550
1,515
1,529
1,522
1,464
1,339
1,307
1,298
1,270
1,257
1,256
1,255
Avg. annual P/E ratio
22.8
22.4
15.8
11.6
11.0
16.5
27.7
11.2
8.5
8.3
20.5
17.5
15.4
706.3
13.6
18.4
P/E to S&P500
1.3
1.0
0.2
0.6
0.7
1.1
1.6
0.6
0.4
0.4
0.9
0.7
0.6
18.7
0.5
0.9
Avg. annual div. yield
- -
- -
- -
- -
- -
- -
- -
- -
1.2%
2.2%
2.9%
3.1%
3.9%
4.0%
4.3%
- -
Revenue (m)
4,230
5,336
7,011
7,949
8,385
9,703
11,202
24,890
32,639
30,390
26,107
22,127
22,449
24,689
27,305
27,281
Operating margin
51.2%
50.2%
50.3%
49.8%
45.2%
41.3%
40.4%
61.3%
68.0%
58.0%
54.1%
37.1%
19.1%
16.5%
36.3%
26.9%
Depreciation (m)
51
102
213
265
302
278
345
1,050
1,098
1,158
1,286
1,429
1,404
1,480
2,050
- -
Net profit (m)
1,615
2,011
2,636
2,901
2,804
2,592
3,075
12,101
18,108
13,501
4,628
5,455
5,386
123
6,225
4,592
Income tax rate
28.9%
26.5%
25.0%
26.2%
23.6%
28.7%
27.3%
18.8%
16.4%
21.1%
65.7%
30.0%
(4.0)%
94.7%
25.1%
21.5%
Net profit margin
38.2%
37.7%
37.6%
36.5%
33.4%
26.7%
27.4%
48.6%
55.5%
44.4%
17.7%
24.7%
24.0%
0.5%
22.8%
16.8%
Working capital (m)
2,292
3,079
2,941
3,243
11,404
1,886
948
11,953
14,872
11,226
20,188
25,231
20,537
4,599
3,162
15,227
Long-term debt (m)
1,312
1,356
1,243
2,946
7,606
7,055
3,939
11,921
21,195
26,346
30,795
24,574
22,094
28,645
25,179
- -
Equity (m)
3,460
4,152
6,367
5,864
6,739
9,310
11,369
15,426
18,534
18,887
20,442
21,387
22,525
18,202
21,069
- -
ROIC
32.6%
36.0%
34.9%
33.6%
20.2%
17.0%
20.8%
43.6%
45.2%
30.2%
8.6%
11.7%
12.4%
0.3%
12.4%
8.4%
Return on capital
39.9%
40.2%
37.5%
35.6%
22.5%
19.0%
20.5%
44.7%
43.6%
32.0%
20.8%
14.0%
10.0%
3.9%
13.7%
10.7%
Return on equity
46.7%
48.4%
41.4%
49.5%
41.6%
27.8%
27.0%
78.4%
97.7%
71.5%
22.6%
25.5%
23.9%
0.7%
29.5%
Infinity%
Plowback ratio
100.0%
100.0%
100.0%
100.0%
100.0%
100.0%
100.0%
100.0%
89.7%
81.8%
41.0%
45.5%
40.2%
(2,704.1)%
42.1%
- -
Div.&Repurch./FCF
14.5%
82.5%
27.2%
137.1%
61.9%
7.2%
9.2%
40.9%
59.0%
83.2%
30.5%
74.7%
57.2%
63.5%
36.9%
- -
Capital Structure
31 Dec · 2022 | Q4
All numbers in millions
Total liabilities
$ - -
Total assets
$ 63,171
Long-term debt
$ - -
Cash and equiv.
$ - -
Goodwill
$ 8,314
Retained earnings
$ 20,916
Common stock
1,252
Enterprise Value
$ 107,691
Working Capital
Currency: USD, in millions
2020
2021
2022
Cash & Investments
7,408
6,520
- -
Receivables
4,892
4,493
4,777
Inventory
1,683
1,618
2,820
Other
2,013
1,482
1,633
Current assets
15,996
14,772
15,227
Acc. Payable
844
705
- -
Debt due
2,757
1,516
- -
Other
7,796
9,389
- -
Current liabilities
11,397
11,610
- -
Annual growth rates
(avg. rate of change)
1 year
5 years
10 years
Revenue
(0.09)%
5.49%
15.45%
Cash flow
(16.04)%
7.33%
36.47%
Earnings
(26.23)%
1,208.94%
567.30%
Dividends
- -
- -
- -
Book value
- -
- -
- -
Insider Trading
Type
Shares
Date
Mercier Johanna
InKind
15,325
01/24/23
Mercier Johanna
Award
38,270
01/24/23
Mercier Johanna
Award
29,124
01/24/23
Dickinson Andrew D
InKind
15,327
01/24/23
Dickinson Andrew D
Award
38,270
01/24/23
Quarterly Revenue
Currency: USD, in millions
Year
1Q
2Q
3Q
4Q
Total
2020
5,548
5,143
6,577
7,421
24,689
2021
6,423
6,217
7,421
7,244
27,305
2022
6,590
6,260
7,042
7,389
27,281
Earnings per share
Currency: USD
Year
1Q
2Q
3Q
4Q
Total
2020
1.23
(2.66)
0.29
1.23
0.10
2021
1.38
1.21
2.06
0.30
4.96
2022
0.02
0.91
1.43
1.31
3.66
Quarterly dividends paid
Currency: USD
Year
1Q
2Q
3Q
4Q
Total
2020
0.70
0.68
0.68
0.68
2.74
2021
0.73
0.71
0.72
0.71
2.87
2022
0.75
0.73
0.74
- -
2.23
Company Description
Sector:
Healthcare
Industry:
Drug Manufacturers—General
CEO:
Mr. Daniel O'Day
Full-time employees:
14,400
City:
Foster City
Address:
333 LAKESIDE DR
IPO:
Jan 1, 1992
Website:
Gilead Sciences, Inc., a biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. The company provides Biktarvy, Genvoya, Descovy, Odefsey, Truvada, Complera/ Eviplera, Stribild, and Atripla products for the treatment of HIV/AIDS; Veklury, an injection for intravenous use, for the treatment of coronavirus disease 2019; and Epclusa, Harvoni, Vosevi, Vemlidy, and Viread for the treatment of liver diseases. It also offers Yescarta, Tecartus, Trodelvy, and Zydelig products for the treatment of hematology, oncology, and cell therapy patients. In addition, the company provides Letairis, an oral formulation for the treatment of pulmonary arterial hypertension; Ranexa, an oral formulation for the treatment of chronic angina; and AmBisome, a liposomal formulation for the treatment of serious invasive fungal infections. Gilead Sciences, Inc. has collaboration agreements with Arcus Biosciences, Inc.; Pionyr Immunotherapeutics Inc.; Tizona Therapeutics, Inc.; Tango Therapeutics, Inc.; Jounce Therapeutics, Inc.; Galapagos NV; Janssen Sciences Ireland Unlimited Company; Japan Tobacco, Inc.; Gadeta B.V.; Bristol-Myers Squibb Company; Dragonfly Therapeutics, Inc.; and Merck & Co, Inc. The company was incorporated in 1987 and is headquartered in Foster City, California.